SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

作者：Hannah C. Lewis, Harriet Ware, Mairead G. Whelan, Lorenzo Subissi, Zihan Li, Xiaomeng Ma, Anthony Nardone, Marta Valenciano, Brianna Cheng, Kim C. Noël, Christian Cao, Mercedes Yanes‐Lane, Belinda Louise Herring, Ambrose Otau Talisuna, Ngoy Nsenga, Thierno Baldé, David A. Clifton, Maria D. Van Kerkhove, David Llewellyn Buckeridge, Niklas Bobrovitz, Joseph Okeibunor, Rahul K. Arora, Isabel Bergeri · 发表于：BMJ Global Health · 年份：2022 · DOI：10.1136/bmjgh-2022-008793 · 被引用次数：167 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 epidemiological studies、SARS-CoV-2 detection and testing

INTRODUCTION: Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on public health and social measures (PHSM) and vaccine strategy. METHODS: We searched for seroprevalence studies conducted in Africa published 1 January 2020-30 December 2021 in Medline, Embase, Web of Science and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity seroprevalence protocol. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO. PROSPERO: CRD42020183634. RESULTS: We identified 56 full texts or early results, reporting 153 distinct seroprevalence studies in Africa. Of these, 97 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% (95% CI 1.0% to 9.2%) in April-June 2020 to 65.1% (95% CI 56.3% to 73.0%) in July-September 2021. The ratios of seroprevalence from infection to cumulative incidence of confirm...